Drug overcomes chemotherapy resistance in ovarian cancer

April 16, 2020

An international research team, led by scientists from Mater Research - The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

Principal Investigator, Professor John Hooper and his team based at the Translational Research Institute (TRI) in Brisbane, Australia, collaborated with researchers from the Queensland University of Technology (QUT) and the Mayo Clinic in the United States of America.

In a pre-clinical study, they found that 2-deoxy-D-glucose, could be used at very low levels to significantly improve the effectiveness of the chemotherapy drug, carboplatin, in treating laboratory models of clear cell ovarian cancer.

Their work, which was published in the scientific journal, Cancers, provides the rationale for a clinical trial to evaluate the use of low-dose 2-deoxy-D-glucose in treating patients with this type of cancer, according to Professor Hooper.

"Ovarian clear cell carcinoma is associated with poor prognosis and resistance to chemotherapy," he said.

"The key finding from our study is that low levels of 2-deoxy-D-glucose markedly improved the efficacy of carboplatin against preclinical models of this ovarian cancer.

"Our pre-clinical work used cells taken from patient tumours, so we were very encouraged that we could use such a low dose of 2-deoxy-D-glucose to overcome resistance to chemotherapy in this cancer and stop tumour growth.

"This drug has been trialled previously in other cancers, but we were able to use a 10-fold lower dose than previously reported so that it's safer for patients and is less likely to cause side-effects."

The team is hoping to begin trialling the treatment combination in patients within the next 12 months, following the announcement they had received an award to progress the ovarian cancer research.

The peak, national gynaecological cancer clinical trials organisation for Australia and New Zealand, ANZGOG, awarded the team its Fund for New Research 2019 - Judith Meschke Memorial Grant to study whether "modulation of metabolism can improve the effectiveness of chemotherapy for clear cell ovarian cancer".

Professor Hooper gratefully acknowledged the generosity of the ANZGOG funding from a bequest of Judith Meschke.

"The involvement in the project of so many talented people, scientists and clinicians, is in the spirit of the creative process fostered by the diverse and talented Australian arts community exemplified by the achievements of Ms Meschke," he said.
-end-


Translational Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.